中国中药杂志

2020, v.45(16) 3967-3973

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

斑蝥胶囊辅助治疗非小细胞肺癌的Meta分析
Meta-analysis of Banmao Capsules in adjuvant treatment for non-small cell lung cancer

徐泳;彭文潘;韩迪;冯凡超;王志超;顾诚;周贤梅;
XU Yong;PENG Wen-pan;HAN Di;FENG Fan-chao;WANG Zhi-chao;GU Cheng;ZHOU Xian-mei;Affiliated Hospital of Nanjing University of Chinese Medicine;

摘要(Abstract):

系统评价斑蝥胶囊辅助治疗非小细胞肺癌(NSCLC)的有效性与安全性。计算机检索PubMed、EMbase、Cochrane Library、中国期刊全文数据库(CNKI)、维普中文科技期刊数据库(VIP)、中国生物医学文献数据库(CBM)、万方数字化期刊全文数据库(WanFang),检索时限为各数据库建库至2019年8月,搜索斑蝥胶囊辅助治疗NSCLC的临床随机对照试验(RCT)。由2名评价者独立评价并交叉核对纳入研究质量,运用RevMan 5.3软件进行Meta分析。共纳入13个RCT,总样本量1 148例,试验组595例,对照组553例。Meta分析显示,与常规治疗相比,斑蝥胶囊辅助治疗NSCLC可以提高肿瘤客观缓解率(RR=1.43,95%CI[1.30,1.58],P<0.01)与疾病控制率(RR=1.16,95%CI[1.11,1.22],P<0.01);改善患者生活质量(RR=1.56,95%CI[1.27,1.92],P<0.01);降低骨髓抑制(RR=0.41,95%CI[0.26,0.66],P<0.01)、胃肠道反应(RR=0.46,95%CI[0.33,0.65],P<0.01)、肝肾功能损害(RR=0.44,95%CI[0.29,0.66],P<0.01)的发生率。斑蝥胶囊辅助治疗NSCLC可以增加近期疗效,改善患者的生活质量,减轻化疗药物的毒副作用。此结论仍需大样本、高质量的RCT来进一步验证。
To systemically evaluate the efficacy and safety of Banmao Capsules in the adjuvant treatment for non-small cell lung cancer(NSCLC). All of randomized controlled trials(RCT) about Banmao Capsules in adjuvant treatment for non-small cell lung cancer were retrieved in PubMed, EMbase, Cochrane Library, CNKI, VIP, CBM, WanFang database from database inception to August 2019. Two researchers extracted data and assessed literature quality separately, and made a Meta-analysis by RevMan 5.3 software. Thirteen trials involving 1 148 patients, including 595 in treatment group and 553 in control group, were enrolled in the review. The Meta-analysis showed that compared with conventional treatment, adjuvant treatment of NSCLC with Banmao Capsules can enhance the objective tumor response rate(RR=1.43,95%CI[1.30,1.58],P<0.01), and the disease control rate(RR=1.16,95%CI[1.11,1.22],P<0.01); improve the quality of life(RR=1.56,95%CI[1.27,1.92],P<0.01); reduce the incidence of myelosuppression(RR=0.41,95%CI[0.26,0.66],P<0.01), gastrointestinal reactions(RR=0.46,95%CI[0.33,0.65],P<0.01), liver and kidney dysfunction(RR=0.44,95%CI[0.29,0.66],P<0.01). The results showed that in the treatment of NSCLC, Banmao Capsules can increase the short-term efficacy, improve the quality of life of patients, and reduce the side effects of platinum-based chemotherapy drugs. More high-quality and large-scale randomized controlled trials are required in the future.

关键词(KeyWords): 斑蝥胶囊;非小细胞肺癌;Meta分析
Banmao Capsules;non-small cell lung cancer;Meta-analysis

Abstract:

Keywords:

基金项目(Foundation): 江苏省研究生科研与实践创新计划项目(KYCX19_1204)

作者(Author): 徐泳;彭文潘;韩迪;冯凡超;王志超;顾诚;周贤梅;
XU Yong;PENG Wen-pan;HAN Di;FENG Fan-chao;WANG Zhi-chao;GU Cheng;ZHOU Xian-mei;Affiliated Hospital of Nanjing University of Chinese Medicine;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享